<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099658</url>
  </required_header>
  <id_info>
    <org_study_id>CIPRA-SA Project 4</org_study_id>
    <secondary_id>U19AI053217</secondary_id>
    <secondary_id>CIPRA</secondary_id>
    <secondary_id>Project 4</secondary_id>
    <nct_id>NCT00099658</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children</brief_title>
  <official_title>Evaluation of Quantitative and Qualitative Antibody Responses to Streptococcus Pneumoniae and Haemophilus Influenzae Type b Conjugate Vaccines Amongst HIV-1-Exposed-Infected Children That Are Receiving Vs. Those Not Receiving Antiretroviral Therapy, as Well as Among HIV-1-Exposed-Uninfected Children and HIV-1-Unexposed-Uninfected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIPRA SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>CIPRA SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection by Streptococcal pneumoniae is a common invasive bacterial infection in HIV
      infected children. The purpose of this study is to determine the safety of and immune
      response to a pneumococcal polysaccharide-protein conjugate vaccine (PncCV) in HIV infected
      and uninfected children. The study will also determine the safety of and immune response to
      Haemophilus influenzae vaccine (HibCV) in these children. Recruitment for this study will
      occur at two hospitals in South Africa, and all HIV infected infants participating in this
      study must also be coenrolled in the CIPRA SA-Project 2 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV infected children are at high risk for invasive pneumococcal disease (IPD) caused by the
      bacterium Streptococcus pneumoniae. Chemoprophylaxis has been used in children with certain
      diseases for the prevention of IPD, but drug resistance may develop with this prevention
      strategy. In contrast, a vaccine to prevent IPD would have fewer negative implications on
      future treatment options than chemoprophylaxis. This study will evaluate the safety of and
      immune response to PncCV in South African HIV infected and uninfected children. This study
      will also evaluate the safety of and immune response to HibCV in these children.

      This study will last 5.5 years. There will be 5 groups in this study. Group 1 will be HIV
      uninfected infants born to HIV uninfected mothers. Group 2 will be HIV infected infants in
      CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA
      SA-Project 2. Group 3 will be HIV infected infants in CDC Disease Category 1 who were
      randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2. Group 4 will
      be HIV infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the
      second early therapy arm (Arm 3) of CIPRA SA-Project 2. Group 5 will be HIV uninfected
      infants born to HIV infected mothers; Group 5 infants will undergo repeat HIV testing at 4 to
      8 months of age, 9 to 11 months of age, and approximately 18 months of age.

      There will be 13 study visits; medical history assessment, a physical examination, and blood
      collection will occur at each visit. At each of 3 study visits before age 24 weeks, all
      participants will receive an injection of PncCV and an injection of routine pediatric
      vaccines, including HibCV. Previously vaccinated HIV infected participants will only receive
      those vaccines they need to complete the South African series of routine pediatric
      vaccinations. Within each group, participants will be randomly assigned to receive a booster
      shot of either PncCV or HibCV between 64 and 76 weeks of age. Participants will also receive
      two measles vaccinations between 38 and 76 weeks of age. Parents or guardians will be asked
      to complete a diary card after each vaccination and report any adverse effects occurring
      within the 72 hours post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to PncCV among children in Group 2 compared to those in Groups 1 and 3</measure>
    <time_frame>At Weeks 3 and 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate to PncCV among children in Group 2 compared to those in Groups 1 and 3 before receiving booster vaccine dose</measure>
    <time_frame>At Weeks 64 through 76</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine safety profiles after each of the three primary doses of PncCV and booster doses of PncCV and HibCV</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">579</enrollment>
  <condition>HIV Infections</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected infants born to HIV-uninfected mothers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected infants born to HIV infected mothers</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal polysaccharide-protein conjugate vaccine</intervention_name>
    <description>Injection administered three times before the age of 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <other_name>PncCV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for All Infants:

          -  Birth weight of at least 2 kg (4.4 lbs)

          -  Written informed consent from parent or guardian

          -  Mother's HIV status documented after 24th week of pregnancy, if her infant joins Group
             5 and is HIV uninfected

          -  Parent or guardian of infant intends to remain in the study area for the duration of
             the trial

        Inclusion Criteria for HIV Infected Infants:

          -  HIV infected

          -  Participating in CIPRA SA-Project 2

        Exclusion Criteria for All Infants:

          -  Blood products prior to study entry

          -  Immunosuppressant agents for more than 2 weeks, within 1 week of study entry

          -  Unable to tolerate oral medications

          -  Presence of any major, life-threatening congenital defect

          -  Acute illness or fever requiring hospitalization within 72 hours of immunization

          -  Grade 2 vaccine-related allergic reaction

          -  Grade 3 or 4 clinical or laboratory toxicity related to vaccination

          -  Use of any antiretroviral therapies other than those allowed in CIPRA SA-Project 2.
             Infants who received antiretroviral drugs used to prevent mother-to-infant HIV
             transmission are eligible for this study.

          -  Use of investigational drugs, systemic cytotoxic chemotherapy, or interleukin or other
             immune modulators

          -  Require certain medications

        Exclusion Criteria for HIV Uninfected Infants:

          -  Vaccines prior to study entry. Infants who have received bacille Calmette-Guerin or
             oral polio vaccines are not excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shabir Madhi, MD, MBBCH, Mmed, FCPaeds, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chris Hani Baragwanath Hospital</affiliation>
  </overall_official>
  <link>
    <url>http://clinicaltrials.gov/ct/show/NCT00102960</url>
    <description>Click here for more information about CIPRA-SA Project 2.</description>
  </link>
  <reference>
    <citation>Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003 Oct 2;349(14):1341-8.</citation>
    <PMID>14523142</PMID>
  </reference>
  <reference>
    <citation>Madhi SA, Kuwanda L, Cutland C, Holm A, KÃ¤yhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005 May;24(5):410-6.</citation>
    <PMID>15876939</PMID>
  </reference>
  <reference>
    <citation>Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2000 Jul;31(1):170-6. Epub 2000 Jul 25.</citation>
    <PMID>10913417</PMID>
  </reference>
  <reference>
    <citation>Nachman S, Kim S, King J, Abrams EJ, Margolis D, Petru A, Shearer W, Smith E, Moye J, Blanchard S, Hawkins E, Bouquin P, Vink P, Benson M, Estep S, Malinoski F; Pediatric AIDS Clinical Trials Group Study 292 Team. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics. 2003 Jul;112(1 Pt 1):66-73.</citation>
    <PMID>12837869</PMID>
  </reference>
  <reference>
    <citation>Pai VB, Heyneman CA, Erramouspe J. Conjugated heptavalent pneumococcal vaccine. Ann Pharmacother. 2002 Sep;36(9):1403-13. Review.</citation>
    <PMID>12196061</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2004</study_first_submitted>
  <study_first_submitted_qc>December 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2004</study_first_posted>
  <last_update_submitted>February 14, 2011</last_update_submitted>
  <last_update_submitted_qc>February 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>James McIntyre</name_title>
    <organization>CIPRA-SA</organization>
  </responsible_party>
  <keyword>MTCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

